quinazolines has been researched along with Thymus Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| He, T; Li, C; Li, X; Luo, Y; Shi, X; Zhao, J; Zu, Y | 1 |
| Akashi, A; Funaki, S; Kadota, Y; Nakagiri, T; Okumura, M; Shiono, H; Takeuchi, Y | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA | 1 |
| Althouse, SK; Burns, M; Gubens, MA; Loehrer, PJ; Pedro-Salcedo, MS; Perkins, SM; Wakelee, HA | 1 |
| Breinig, M; Chiosis, G; Dienemann, H; Giaccone, G; Goeppert, B; Harjung, A; Hartmann, A; Kern, MA; Malz, M; Mayer, P; Neumann, O; Penzel, R; Rieker, RJ; Schirmacher, P | 1 |
| Koshiishi, H; Takahashi, E; Takahashi, M | 1 |
1 review(s) available for quinazolines and Thymus Neoplasms
| Article | Year |
|---|---|
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult | 2015 |
2 trial(s) available for quinazolines and Thymus Neoplasms
| Article | Year |
|---|---|
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Carcinoma; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Humans; Male; Middle Aged; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; src-Family Kinases; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Failure; Young Adult | 2015 |
4 other study(ies) available for quinazolines and Thymus Neoplasms
| Article | Year |
|---|---|
Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion.
Topics: Antineoplastic Agents; Crown Ethers; ErbB Receptors; Exons; Humans; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion; Thymoma; Thymus Neoplasms | 2021 |
Does gefitinib have effects on EGFR mutation-positive thymoma? -Case report of thymoma recurrence.
Topics: Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Reoperation; Thoracic Surgery, Video-Assisted; Thymoma; Thymus Neoplasms | 2014 |
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
Topics: Aged; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Infant; Infant, Newborn; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Thymus Neoplasms | 2011 |
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].
Topics: Adult; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Recurrence; Thymoma; Thymus Neoplasms | 2011 |